TCR² Therapeutics to Host R&D Day on October 20, 2021
October 13 2021 - 6:45AM
TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell
therapy company with a pipeline of novel T cell therapies for
patients suffering from cancer, today announced that it will host a
virtual R&D Day for analysts and investors at 8:00a.m. ET on
Wednesday, October 20, 2021.
The meeting will feature updates on the
Company’s emerging oncology pipeline including enhancements, novel
targets and allogeneic TRuCs as well as TRuC Tregs for autoimmune
diseases. Speakers will include:
- Garry Menzel,
Ph.D., President and Chief Executive Officer
- Alfonso
Quintás-Cardama, M.D., Chief Medical Officer
- Robert
Hofmeister, Ph.D., Chief Scientific Officer
- Robert Tighe,
Vice President of Translational Research
- Raffit Hassan,
M.D., Chief of Thoracic and GI Malignancies Branch at the National
Cancer Institute
To register for the virtual event or watch a live webcast of the
presentation, please visit the Investors page of the Company’s
website at investors.tcr2.com. An archived replay will be available
for at least 30 days following the presentation.
About TCR2
Therapeutics
TCR2 Therapeutics Inc. is a
clinical-stage cell therapy company developing a pipeline of novel
T cell therapies for patients suffering from
cancer. TCR2’s proprietary T cell receptor (TCR) Fusion
Construct T cells (TRuC®-T cells) specifically recognize and
kill cancer cells by harnessing signaling from the entire TCR,
independent of human leukocyte antigens (HLA). In preclinical
studies, TRuC-T cells have demonstrated superior anti-tumor
activity compared to chimeric antigen receptor T cells (CAR-T
cells), while secreting lower levels of cytokine release. The
Company’s lead TRuC-T cell product candidate targeting solid
tumors, gavocabtagene autoleucel (“gavo-cel”), is currently being
studied in a Phase 1/2 clinical trial to treat patients with
mesothelin-positive non-small cell lung cancer (NSCLC), ovarian
cancer, malignant pleural/peritoneal mesothelioma, and
cholangiocarcinoma. The Company’s lead TRuC-T cell product
candidate targeting hematological malignancies, TC-110, is
currently being studied in a Phase 1/2 clinical trial to treat
patients with CD19-positive adult acute lymphoblastic leukemia
(aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL).
For more information about TCR2, please
visit www.tcr2.com.
Investor and Media Contact:
Carl MauchDirector, Investor Relations and
Corporate CommunicationsTCR2 Therapeutics Inc.(617)
949-5667carl.mauch@tcr2.com
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Aug 2024 to Sep 2024
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Sep 2023 to Sep 2024